Investing since 2009, we focus exclusively on novel, transformational therapeutics at discovery and pre-clinical stages. Aligning with AbbVie’s strategic focus, our investments address critical needs in oncology, immunology, and neuroscience. We offer our partners access to AbbVie’s vast internal network of experts in all phases of drug development, from drug discovery through successful commercialization.
Our current portfolio is comprised of more than a dozen companies based in the US and Europe. Targeting 6-8 new investments annually, at the Seed or Series A stage, we have the capability and flexibility to lead or co-lead a syndicate. Our team of eight investing professionals is based in three locations: Boston, San Francisco and Chicago areas.